公开(公告)号：US20150183884A1

公开(公告)日：2015-07-02

申请号：US14142186

申请日：2013-12-27

Applicant: NATIONAL HEALTH RESEARCH INSTITUTES ,  DEVELOPMENT CENTER FOR BIOTECHNOLOGY

Inventor： Shih-Chong Tsai ,  Neng-Yao Shih ,  Ta-Tung Yuan ,  Ko-Jiunn Liu ,  Shih-Chi Tseng ,  Chih-Yung Hu ,  Hsin-Yun Wang ,  Li-Tzong Chen

IPC: C07K16/40 ,  G01N33/574

CPC classification number: C07K16/40 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/57492 ,  G01N2333/988

Abstract: The present invention discloses an anti-human alpha-enolase (ENO1) antibody, which can bind the peptides, comprising amino-acid sequence 296FD Q D D W G A W Q K F TA309 (SEQ ID: #9) and/or 326K R I A K A V N EK S336 (SEQ ID: #10) of human ENO1 protein (GenBank: AAH50642.1), has a favorable binding activity (the binding affinity is around 2.19×10-10 mol/L) and a remarkable capability to inhibit the cell invasion and tumor metastasis of a varied of tumors. The recognized peptides and antibody of the invention are useful for diagnosis, prognosis, and treatment of cancers that have been reported to express cell-surface ENO1 such as including lung, breast, pancreas, liver, colorectal, prostate cancers and solid tumors.

Abstract translation: 本发明公开了可以结合肽的抗人α-烯醇酶（ENO1）抗体，其包含氨基酸序列296FD QDDWGAWQKF TA309（SEQ ID：＃9）和/或326K RIAKAVN EK S336（SEQ ID＃＃10 ）的人类ENO1蛋白（GenBank：AAH50642.1）具有良好的结合活性（结合亲和力约为2.19×10 -10 mol / L），并且具有显着的抑制多种肿瘤细胞侵袭和肿瘤转移的能力 。 公认的本发明的肽和抗体可用于已经报道表达细胞表面ENO1的癌症的诊断，预后和治疗，所述癌症包括肺，乳腺，胰腺，肝脏，结肠直肠癌，前列腺癌和实体瘤。

公开(公告)号：US20150175710A1

公开(公告)日：2015-06-25

申请号：US14580127

申请日：2014-12-22

Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY

Inventor： Shih-Chong Tsai ,  Mingl Chang ,  Ta-Tung Yuan ,  Shih-Chi Tseng ,  Shyi-Jou Chen ,  Wei-Tso Chia ,  Hsin-Yun Wang

IPC: C07K16/40 ,  A61K39/39 ,  A61K39/395

CPC classification number: A61K39/39 ,  A61K39/3955 ,  A61K2039/505 ,  B63B1/121 ,  B63B15/02 ,  B63B2001/123 ,  B63B2015/005 ,  B63H9/08 ,  C07K16/40 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/92

Abstract: A method for treating an inflammatory disease or an immune disorder includes administering to a subject in need of such treatment an antagonist against ENO1. The antagonist binds ENO1 and inhibits ENO1 plasminogen receptor activity. The antagonist may be an anti-human ENO1 antibody, or an scFv, Fab, or F(ab)2 fragment thereof, that specifically binds to human ENO1 (GenBank: AAH50642.1) for the treatment of an inflammatory disease or an immune disorder, which may be multiple sclerosis, rheumatoid arthritis, Crohn's disease, ulcerative colitis, systemic Lupus erythematosus, chronic obstructive pulmonary disease (COPD), asthma, allergy, psoriasis, type 1 diabetes mellitus, artherosclerosis or osteoporosis.

Abstract translation: 用于治疗炎性疾病或免疫疾病的方法包括向需要这种治疗的受试者施用针对ENO1的拮抗剂。 拮抗剂结合ENO1并抑制ENO1纤溶酶原受体活性。 拮抗剂可以是特异性结合人ENO1（GenBank：AAH50642.1）用于治疗炎性疾病或免疫疾病的抗人ENO1抗体或其scFv，Fab或F（ab）2片段） ，可能是多发性硬化症，类风湿性关节炎，克罗恩病，溃疡性结肠炎，系统性红斑狼疮，慢性阻塞性肺病（COPD），哮喘，过敏，牛皮癣，1型糖尿病，动脉粥样硬化或骨质疏松症。

公开(公告)号：US09750804B2

公开(公告)日：2017-09-05

申请号：US14580127

申请日：2014-12-22

Applicant: Development Center for Biotechnology ,  National Health Research Institutes

Inventor： Shih-Chong Tsai ,  Mingl Chang ,  Ta-Tung Yuan ,  Shih-Chi Tseng ,  Shyi-Jou Chen ,  Wei-Tso Chia ,  Hsin-Yun Wang ,  Neng-Yao Shih ,  Ko-Jiunn Liu ,  Li-Tzong Chen

IPC: C07K16/28 ,  A61K39/39 ,  B63B15/02 ,  A61K39/395 ,  C07K16/40 ,  B63B1/12 ,  B63H9/08 ,  B63B15/00 ,  A61K39/00

CPC classification number: A61K39/39 ,  A61K39/3955 ,  A61K2039/505 ,  B63B1/121 ,  B63B15/02 ,  B63B2001/123 ,  B63B2015/005 ,  B63H9/08 ,  C07K16/40 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/92

Abstract: A method for treating an inflammatory disease or an immune disorder includes administering to a subject in need of such treatment an antagonist against ENO1. The antagonist binds ENO1 and inhibits ENO1 plasminogen receptor activity. The antagonist may be an anti-human ENO1 antibody, or an scFv, Fab, or F(ab)2 fragment thereof, that specifically binds to human ENO1 (GenBank: AAH50642.1) for the treatment of an inflammatory disease or an immune disorder, which may be multiple sclerosis, rheumatoid arthritis, Crohn's disease, ulcerative colitis, systemic Lupus erythematosus, chronic obstructive pulmonary disease (COPD), asthma, allergy, psoriasis, type 1 diabetes mellitus, artherosclerosis or osteoporosis.

公开(公告)号：US09382331B2

公开(公告)日：2016-07-05

申请号：US14142186

申请日：2013-12-27

Applicant: Development Center for Biotechnology ,  National Health Research Institutes

Inventor： Shih-Chong Tsai ,  Neng-Yao Shih ,  Ta-Tung Yuan ,  Ko-Jiunn Liu ,  Shih-Chi Tseng ,  Chih-Yung Hu ,  Hsin-Yun Wang ,  Li-Tzong Chen

IPC: A61K39/395 ,  C07K16/40 ,  G01N33/574 ,  A61K39/00

CPC classification number: C07K16/40 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/57492 ,  G01N2333/988

Abstract: The present invention discloses an anti-human alpha-enolase (ENO1) antibody, which can bind the peptides, comprising amino-acid sequence 296FD Q D D W G A W Q K F TA309 (SEQ ID: #9) and/or 326K R I A K A V N EK S336 (SEQ ID: #10) of human ENO1 protein (GenBank: AAH50642.1), has a favorable binding activity (the binding affinity is around 2.19×10-10 mol/L) and a remarkable capability to inhibit the cell invasion and tumor metastasis of a varied of tumors. The recognized peptides and antibody of the invention are useful for diagnosis, prognosis, and treatment of cancers that have been reported to express cell-surface ENO1 such as including lung, breast, pancreas, liver, colorectal, prostate cancers and solid tumors.

Abstract translation: 本发明公开了可以结合肽的抗人α-烯醇酶（ENO1）抗体，其包含氨基酸序列296FD QDDWGAWQKF TA309（SEQ ID：＃9）和/或326K RIAKAVN EK S336（SEQ ID＃＃10 ）的人类ENO1蛋白（GenBank：AAH50642.1）具有良好的结合活性（结合亲和力约为2.19×10 -10 mol / L），并且具有显着的抑制多种肿瘤细胞侵袭和肿瘤转移的能力 。 公认的本发明的肽和抗体可用于已经报道表达细胞表面ENO1的癌症的诊断，预后和治疗，所述癌症包括肺，乳腺，胰腺，肝脏，结肠直肠癌，前列腺癌和实体瘤。